Phaseline

Targets › NDMA1

NDMA1: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 4; Genitourinary; next expected readout Jun 2029.

Open in Phaseline: the race on NDMA1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Rutgers, The State University of New JerseyIsoniazid
Enoyl-[acyl-carrier-protein] reductase inhibitor
NDMA1Phase 4Latent TuberculosisJun 2029

Conditions

Latent Tuberculosis (1)

Modalities

small molecule (1)

Companies

Rutgers, The State University of New Jersey (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.